A Phase I Adaptive Dose, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT118335 in Healthy Subjects

Trial Profile

A Phase I Adaptive Dose, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT118335 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs CORT 118335 (Primary) ; Prednisone
  • Indications Metabolic disorders; Non-alcoholic fatty liver disease
  • Focus Adverse reactions; First in man
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 02 Jul 2018 Number of treatment arms and planned patient number has been changed. Drug dosage have been changed.
    • 02 Jul 2018 Planned number of patients changed from 128 to 136.
    • 02 Jul 2018 Planned End Date changed from 1 Mar 2018 to 5 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top